Markets:

Overview

News

Currencies

International

Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

5.670 -0.140 (-2.41%)

Streaming Delayed Price Updated: 1:08 PM EDT, Mar 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Verastem, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Verastem (VSTM) Q4 2025 Earnings Call Transcript ↗

March 05, 2026

Verastem (VSTM) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? ↗

March 04, 2026

The company flagged several catalysts ahead, including early VS-7375 data in the first half of the year, and Ramp 205 pancreatic cancer study results in Q2.

Via Stocktwits

Topics Earnings

Verastem Inc. (NASDAQ:VSTM) Reports Strong Q4 Revenue Beat, Narrows Loss Amid Product Launch ↗

March 04, 2026

Via Chartmill

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

A full exit during a volatile stretch raises a sharper question than timing alone.

Via The Motley Fool

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects ↗

October 24, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer ↗

December 29, 2025

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data.

Via Stocktwits

Topics Supply Chain

This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗

December 28, 2025

When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.

Via The Motley Fool

Topics Regulatory Compliance

ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗

December 28, 2025

ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.

Via The Motley Fool

Topics Regulatory Compliance

Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

November 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 14, 2025

Via Benzinga

Verastem Inc (NASDAQ:VSTM) Reports Q3 2025 Revenue Beat Amid Widened Loss ↗

November 04, 2025

Verastem's Q3 2025 results show a strong revenue beat from its new cancer drug launch, while its net loss widened. The stock dipped slightly on the mixed earnings news.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 13, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

August 13, 2025

After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish ↗

June 02, 2025

In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell...

Via Stocktwits

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 02, 2025

Via Benzinga

Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May ↗

June 02, 2025

Via Benzinga

What's Going On With Verastem Oncology Stock On Monday? ↗

June 02, 2025

Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities across tested doses.

Via Benzinga

Which stocks are experiencing notable movement on Monday? ↗

June 02, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer ↗

May 08, 2025

FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments.

Via Benzinga

Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased ↗

May 08, 2025

The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian...

Via Stocktwits

9 Health Care Stocks With Whale Alerts In Today's Session ↗

April 22, 2025

Via Benzinga

This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

April 10, 2025

Via Benzinga

Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

March 18, 2025

Via Benzinga

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket ↗

March 18, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 31, 2024

Via Benzinga

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday? ↗

December 31, 2024

Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 17, 2024

Via Benzinga

VSTM Stock Earnings: Verastem Beats EPS, Beats Revenue for Q2 2024 ↗

August 09, 2024

VSTM stock results show that Verastem beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.